Therapeutic drug monitoring of immunosuppressant drugs.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 2014241)

Published in Br J Clin Pharmacol on April 01, 1999

Authors

A Johnston1, D W Holt

Author Affiliations

1: The Analytical Unit, Cardiological Sciences, St George's Hospital Medical School, London SW17 ORE, UK.

Articles cited by this

(truncated to the top 100)

Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions (1976) 9.68

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell (1992) 8.51

Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature (1992) 8.15

The mechanism of action of cyclosporin A and FK506. Immunol Today (1992) 7.57

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med (1998) 3.76

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71

Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet (1995) 3.49

The IL-2/IL-2 receptor system: a current overview. Cell (1993) 3.33

The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol (1993) 2.96

Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem (1998) 2.85

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 2.80

Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet (1998) 2.42

Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96

Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol (1991) 1.67

The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther (1998) 1.42

Therapeutic drug monitoring. Clin Pharmacol Ther (1988) 1.40

Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30

Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev (1993) 1.28

An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation (1996) 1.27

Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem (1990) 1.16

Mycophenolate mofetil. Lancet (1996) 1.12

Limit of quantification (functional sensitivity) of the new IMx Tacrolimus II microparticle enzyme immunoassay. Clin Chem (1998) 1.09

Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol (1999) 1.06

Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc (1996) 1.05

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet (1998) 1.05

Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther (1993) 1.05

Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord (1996) 1.04

The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. Transplant Proc (1994) 1.02

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem (1998) 1.01

The discovery and development of cyclosporine (Sandimmune). Transplant Proc (1991) 1.00

The United Kingdom Cyclosporin Quality Assessment Scheme. Ther Drug Monit (1986) 0.96

Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin Chem (1998) 0.96

Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc (1998) 0.96

Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem (1998) 0.93

Xenotransplantation: problems and prospects. Annu Rev Med (1998) 0.92

Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit (1995) 0.92

Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator. Int J Urol (1995) 0.92

Measurement of cyclosporine: methodological problems. Transplant Proc (1986) 0.91

Sirolimus: a new agent for clinical renal transplantation. Transplant Proc (1997) 0.90

Immunological monitoring of azathioprine treatment in multiple sclerosis patients. J Neurol (1997) 0.89

Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit (1995) 0.88

Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. Transplant Proc (1991) 0.87

Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Ther Drug Monit (1996) 0.87

Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation (1996) 0.87

Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther (1998) 0.86

The history of cyclosporin A (Sandimmune) revisited: another point of view. Experientia (1996) 0.85

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem (1998) 0.85

A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc (1990) 0.84

Blood cyclosporin concentrations and renal allograft dysfunction. Br Med J (Clin Res Ed) (1986) 0.84

Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem (1996) 0.84

Concentration-controlled trials. What does the future hold? Clin Pharmacokinet (1995) 0.84

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation (1997) 0.83

Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. Eur J Clin Pharmacol (1994) 0.83

Cyclosporine plasma levels six hours after oral administration. A useful tool for monitoring therapy. Transplantation (1988) 0.83

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs (1996) 0.83

Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation (1995) 0.82

Modes of action of FK506, cyclosporin A, and rapamycin. Transplant Proc (1994) 0.82

Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry. Clin Chem (1997) 0.81

Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem (1990) 0.81

Target concentration strategy for cyclosporin monitoring. Clin Pharmacokinet (1997) 0.81

Sirolimus in transplantation. Arch Immunol Ther Exp (Warsz) (1997) 0.81

Neoral in liver transplantation. Transplant Proc (1996) 0.80

Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem (1998) 0.80

Optimizing the use of cyclosporine in renal transplantation. Clin Biochem (1995) 0.80

Mycophenolic acid (NSC-129185): preliminary clinical trials. Cancer Chemother Rep (1972) 0.80

Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). Transplant Proc (1998) 0.80

Total testing process applied to therapeutic drug monitoring: impact on patients' outcomes and economics. Clin Chem (1998) 0.80

Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation (1995) 0.79

Preclinical evaluation of a new immunosuppressive agent, FTY720. Clin Biochem (1998) 0.79

Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure. The Collaborative Transplant Study. Kidney Int Suppl (1995) 0.79

An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. Ther Drug Monit (1998) 0.79

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation (1997) 0.78

Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc (1996) 0.78

Generic substitution for cyclosporine: what should we be looking for in new formulations? Transplant Proc (1998) 0.78

A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol (1990) 0.78

Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit (1995) 0.78

Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. J Biopharm Stat (1996) 0.78

The present position and future prospects of organ transplantation. Ann R Coll Surg Engl (1968) 0.78

Cyclosporin A: analytical methodology and factors affecting therapeutic drug monitoring. Ther Drug Monit (1995) 0.77

Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. Ther Drug Monit (1998) 0.77

Predicting patients' exposure to cyclosporin. Transpl Int (1996) 0.77

[Not Available]. BioDrugs (1997) 0.77

Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients. Clin Transplant (1997) 0.77

Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit (1995) 0.77

Sandimmun neoral pharmacokinetics: impact of the new oral formulation. Transplant Proc (1995) 0.77

Calibration of the CYCLO-Trac SP cyclosporine radioimmunoassay. Clin Chem (1993) 0.76

Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. Transplant Proc (1996) 0.76

Changing stable heart transplant recipients from Sandimmune to Neoral. Transplant Proc (1996) 0.76

Monitoring of TPMT in heart transplant recipients under immunosuppressive therapy with azathioprine. Artif Organs (1995) 0.76

Quality assessment issues of new immunosuppressive drugs and experimental experience. Ther Drug Monit (1996) 0.76

Monitoring antithymocyte globulin in renal transplantation. Ann R Coll Surg Engl (1996) 0.76

Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients. Transpl Int (1996) 0.76

OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry. Transplant Proc (1996) 0.76

Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis. Ophthalmology (1997) 0.76

Immunosuppressive protocols for renal transplantation. Nephrol Dial Transplant (1997) 0.76

New immunologically non-specific immunosuppressive agents dictate changes in standard protocols for renal transplant management. Nephrol Dial Transplant (1997) 0.76

Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem (1994) 0.76

Organ transplantation. The present position and future prospects of organ transplantation. Trans Med Soc Lond (1969) 0.76

Tacrolimus quality assessment. Ther Drug Monit (1997) 0.76

Articles by these authors

(truncated to the top 100)

Side effects of long-term amiodarone therapy. Circulation (1983) 3.03

Fatal overdosage with disopyramide. Lancet (1978) 2.96

Smoking and decreased fertilisation rates in vitro. Lancet (1992) 2.92

Purchasing 'legal highs' on the Internet--is there consistency in what you get? QJM (2010) 2.43

Amiodarone pharmacokinetics. Am Heart J (1983) 2.42

Comparison of two strategies for myocardial management during coronary artery operations. Ann Thorac Surg (1994) 2.21

Measuring brain natriuretic peptide. Lancet (1996) 2.03

Evaluation of fetal arrhythmias by echocardiography. Br Heart J (1983) 1.59

Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J (2001) 1.54

Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit (1997) 1.48

TGF-beta quantitation can be tricky. Transplantation (1999) 1.47

A controlled trial of substrate-enhanced, warm reperfusion ("hot shot") versus simple reperfusion. Ann Thorac Surg (2000) 1.38

The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med (2009) 1.36

High-performance liquid chromatographic measurement of amiodarone and its desethyl metabolite: methodology and preliminary observations. Ther Drug Monit (1982) 1.31

Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr (1981) 1.26

Paediatric use of mexiletine and disopyramide. Br Med J (1979) 1.23

Amiodarone in testis and semen. Lancet (1985) 1.20

Buying 'legal' recreational drugs does not mean that you are not breaking the law. QJM (2010) 1.19

Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit (2001) 1.17

Death rate from use of ecstasy or heroin. Lancet (2000) 1.12

Amiodarone in pregnancy. Lancet (1983) 1.11

Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation (1985) 1.07

Postmortem assay of digoxin by radioimmunoassay. J Clin Pathol (1975) 1.06

Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM (2008) 1.05

Amiodarone pharmacokinetics. Br J Clin Pract Suppl (1986) 1.02

Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. J Chromatogr (1980) 1.02

Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem (1998) 1.01

Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J (1995) 1.01

High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in small tissue samples after enzymatic digestion. J Clin Pathol (1983) 1.00

Cardiac troponins and creatine kinase content of striated muscle in common laboratory animals. Clin Chim Acta (2001) 0.99

Accuracy of cyclosporin measurements made in capillary blood samples obtained by skin puncture. Ther Drug Monit (2000) 0.98

Intravenous and oral amiodarone for arrhythmias in children. Br Heart J (1986) 0.98

HPLC assay with ultraviolet detection for therapeutic drug monitoring of sirolimus. Clin Chem (2001) 0.97

Lack of response to intravenous calcium in severe verapamil poisoning. Lancet (1982) 0.97

An immunoassay for the measurement of sirolimus. Clin Ther (2000) 0.96

Mexiletine for control of ventricular dysrhythmias in pregnancy. Lancet (1980) 0.96

The United Kingdom Cyclosporin Quality Assessment Scheme. Ther Drug Monit (1986) 0.96

Peripheral neutrophil inclusions in amiodarone treated patients. Br J Clin Pharmacol (1986) 0.95

The pathogenesis of amiodarone-induced pigmentation and photosensitivity. Br J Dermatol (1984) 0.95

Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. J Pharm Pharmacol (1982) 0.95

A new method to monitor drugs at dance venues. BMJ (2001) 0.93

Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit (1995) 0.92

Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation (1986) 0.92

Measurement of cyclosporine: methodological problems. Transplant Proc (1986) 0.91

High-performance liquid chromatographic measurement of atenolol: methodology and clinical applications. Ther Drug Monit (1983) 0.91

Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int (2000) 0.91

Simple gas-liquid chromatographic method for the measurement of mexiletine and lignocaine in blood-plasma or serum. J Chromatogr (1979) 0.90

Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide. Br J Clin Pharmacol (1983) 0.89

Neuropsychological change and S-100 protein release in 130 unselected patients undergoing cardiac surgery. Stroke (1999) 0.89

Serum neopterin in acute coronary syndromes. Lancet (1997) 0.87

Hepatic effects of amiodarone. Br J Clin Pract Suppl (1986) 0.86

Bioavailability of amiodarone. Eur J Clin Pharmacol (1984) 0.86

Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob Chemother (2010) 0.86

Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther (1999) 0.85

Gas-liquid chromatographic measurement of lignocaine in small samples of canine myocardium after enzymatic digestion. J Clin Pathol (1979) 0.85

Use of troponin-T concentration and kinase isoforms for quantitation of myocardial injury induced by radiofrequency catheter ablation. Eur Heart J (1997) 0.85

Circulating cardiac troponin-T in patients before and after renal transplantation. Clin Chim Acta (2001) 0.84

A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc (1990) 0.84

Therapeutic drug monitoring of cyclosporine. Transplant Proc (2004) 0.84

Blood cyclosporin concentrations and renal allograft dysfunction. Br Med J (Clin Res Ed) (1986) 0.84

High-performance liquid chromatographic method for the measurement of mexiletine and flecainide in blood plasma or serum. J Chromatogr (1984) 0.84

Concentration-controlled trials. What does the future hold? Clin Pharmacokinet (1995) 0.84

Plasma disopyramide concentrations following a 300-mg oral loading dose in acute myocardial infarction. Ther Drug Monit (1982) 0.83

Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit (1995) 0.83

Creatine kinase MB isoforms: sensitive markers of ischemic myocardial damage. Clin Chem (1994) 0.83

Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. Br Heart J (1989) 0.83

Use of amiodarone and digoxin specific Fab antibodies in digoxin overdosage. Br Heart J (1985) 0.82

High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in plasma or serum at the concentrations attained following a single 400-mg dose. J Chromatogr (1982) 0.82

What evidence is there that the UK should tackle the potential emerging threat of methamphetamine toxicity rather than established recreational drugs such as MDMA ('ecstasy')? QJM (2008) 0.82

Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med (2011) 0.82

Experience with flecainide for the treatment of cardiac arrhythmias in children. Eur Heart J (1988) 0.82

Use of amiodarone during pregnancy. Postgrad Med J (1985) 0.81

Experimental disopyramide poisoning: treatment by cardiovascular support and with charcoal hemoperfusion. J Pharmacol Exp Ther (1979) 0.81

Myocardial injury induced by radiofrequency and low energy ablation: a quantitative study of CK isoforms, CK-MB, and troponin-T concentrations. Pacing Clin Electrophysiol (1998) 0.81

The effect of vehicle on the oral absorption of cyclosporin. Br J Clin Pharmacol (1986) 0.81

Cardiac consequences and treatment of disopyramide intoxication: experimental evaluation in dogs. Cardiovasc Res (1979) 0.81

Cardiac troponin T and creatine kinase MB are not increased in exterior oblique muscle of patients with renal failure. Clin Chem (2001) 0.81

Immunosuppressant drugs--the role of therapeutic drug monitoring. Br J Clin Pharmacol (2001) 0.81

Osteoarthritis in temporomandibular joint of Col2a1 mutant mice. Arch Oral Biol (2013) 0.81

The digoxin-amiodarone interaction. Cardiovasc Drugs Ther (1989) 0.81

Optimizing the use of cyclosporine in renal transplantation. Clin Biochem (1995) 0.80

Elevated serum levels of soluble interleukin-2 receptor, neopterin and beta-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis. Eur J Heart Fail (2001) 0.80

Treatment of disopyramide overdosage. Med J Aust (1979) 0.80

Which cyclosporin formulation? Lancet (1996) 0.79

Verapamil and breast-feeding. Eur J Clin Pharmacol (1986) 0.79

Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. Transplant Proc (1991) 0.79

Electrophysiological properties of mexiletine assessed with respect to plasma concentrations. Eur J Cardiol (1980) 0.79

Can vacuum assisted venous drainage be achieved using a roller pump in an emergency? A pilot study using neonatal circuitry. J Extra Corpor Technol (2007) 0.79

Convulsion after disopyramide. Lancet (1978) 0.79

Generic substitution for cyclosporine: what should we be looking for in new formulations? Transplant Proc (1998) 0.78

Class III antiarrhythmics in overdose. Presenting features and management principles. Drug Saf (1993) 0.78

Troponin T as a non-invasive marker of cardiac allograft rejection. Lancet (1993) 0.78

HPLC measurement of diltiazem and desacetyldiltiazem in serum or plasma. Biomed Chromatogr (1987) 0.78

CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients. Ther Drug Monit (2013) 0.78

A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients. Transplant Proc (2004) 0.78

Renal elimination of amiodarone and its desethyl metabolite. Postgrad Med J (1983) 0.78

Is fibreoptic bronchoscopy in patients with lung cancer and hepatic metastases potentially dangerous? Br J Dis Chest (1985) 0.77

Cyclosporin and vitamin E. Lancet (1991) 0.77

Clinically significant interaction between digoxin and quinidine. Br Med J (1979) 0.77

Essential hypertension and pregnancy: successful outcome with atenolol. Br J Clin Pract (1984) 0.77